Upload
Featured Recent Articles Topics Login Upload

Search Results for 'drug rare'

drug rare published presentations and documents on DocSlides.

Tackling Rare Diseases
Tackling Rare Diseases
by conchita-marotz
in the United States. Paul Melmeyer. Associate. ...
Improving the process of rare disease treatment development
Improving the process of rare disease treatment development
by lindy-dunigan
“. EMERGING THERAPIES FOR RARE DISEASES. ”. ...
The Rare Disease Treatment Approval Process:
The Rare Disease Treatment Approval Process:
by lily
Balancing Gold Standard Evidence with Patient-Cent...
Clinical Investigator Training Course
Clinical Investigator Training Course
by luanne-stotts
Issues in Clinical Trial Design for Rare Diseases...
Going Beyond the Current Regulatory and Incentives Framewor
Going Beyond the Current Regulatory and Incentives Framewor
by calandra-battersby
A new proposal to foster greater orphan drug deve...
October RDLA Lunch Meeting/Webinar
October RDLA Lunch Meeting/Webinar
by tawny-fly
Oct. 16th, 2014. The National Association of Insu...
The Budget Impact of Drugs Treating Rare Diseases in Canada
The Budget Impact of Drugs Treating Rare Diseases in Canada
by myesha-ticknor
: A 2007-2013 MIDAS Sales Data Analysis. April 14...
The Budget Impact of Drugs Treating Rare Diseases in Canada
The Budget Impact of Drugs Treating Rare Diseases in Canada
by phoebe-click
: A 2007-2013 MIDAS Sales Data Analysis. April 14...
Advocacy 101 Kristen Angell, Associate Director of
Advocacy 101 Kristen Angell, Associate Director of
by jubilantbikers
Advocacy. National Organization for Rare Disorders...
6. Priority diseases and reasons for
6. Priority diseases and reasons for
by kaptainpositive
inclusion 1 6.19 Rare diseases See Background Pape...
CHI-California Healthcare Institute is a non-profit public policy rese
CHI-California Healthcare Institute is a non-profit public policy rese
by bigboybikers
biomedical R&D industry. CHI represents more than ...
Changing the trajectory of drug R&D
Changing the trajectory of drug R&D
by della
Robert Plenge, MD, PhD. ASBMR. September 15, 2016....
Orphan Drug Global Incentives & Regulatory Framework
Orphan Drug Global Incentives & Regulatory Framework
by pasty-toler
Marlene E. Haffner, MD, MPH. CEO, Haffner Associ...
Presentation To : The Jackson Laboratory
Presentation To : The Jackson Laboratory
by isla
Chris Hempel. Addi & Cassi Fund. A Family’s ...
from WikiPedia
from WikiPedia
by caroline
CS201 – Bayes ’ Theorem – Excerpts http:/...
Translational Research through Public-Private Partnerships
Translational Research through Public-Private Partnerships
by faustina-dinatale
65. th. Annual . Bohan. Lecture. Scott J. Weir...
Rare vs. common gene variants
Rare vs. common gene variants
by emery
as guides to pain mechanisms . and drug developmen...
December, 2021 Corporate Overview: Non-Confidential
December, 2021 Corporate Overview: Non-Confidential
by elysha
page . 1. CAUTIONARY STATEMENT REGARDING FORWARD-L...
Hypoparathyroidism (hypoPARA) – A RARE, COMPLEX DISORDER
Hypoparathyroidism (hypoPARA) – A RARE, COMPLEX DISORDER
by crunchingsubway
1. Disclaimer. Prepared by non-medical personnel. ...
March 20th,
March 20th,
by lois-ondreau
2014. Potential elimination of the Orphan Drug ...
FP7 Projects in Rare
FP7 Projects in Rare
by olivia-moreira
Anaemias. : . DEEP - . Deferiprone. Evaluation i...